PURPOSE:Rituximab is a chimeric antibody that induces B-cell apoptosis and recruits immune effector cells to mediate cell lysis. Interleukin-12 (IL-12) facilitates cytolytic responses by T cells and natural killer cells. This phase II study was done to determine the efficacy and toxicity of IL-12 in combination with rituximab in patients with B-cell non-Hodgkin's lymphoma (NHL). EXPERIMENTAL DESIGN:Fifty-eight patients with histologically confirmed relapsed B-cell NHL were randomized to receive concurrent treatment with rituximab and IL-12 (arm A) or rituximab with subsequent treatment with IL-12 after documented nonresponse or progression after rituximab (arm B). Treatment consisted of 375 mg/m2 rituximab on days 1, 8, 15, and 22 and 300 ng/kg IL-12 given s.c. twice weekly starting on day 2 for arm A or upon progression for arm B. RESULTS: The overall response rate was 37% (11 of 30) in arm A and 52% (13 of 25) in arm B. All of the responses seen in arm B occurred while patients received rituximab, and no responses occurred during treatment with subsequent IL-12. The median duration of response was 16 months for arm A and 12 months for arm B. Biopsy specimens were serially obtained in a subset of patients and showed that changes in gene expression were different when cells from the peripheral blood were compared with cells from lymph node biopsies. CONCLUSIONS: The concomitant use of IL-12 and rituximab had modest disease activity in patients with B-cell NHL, but the sequential administration of IL-12 after rituximab did not result in additional clinical responses.
RCT Entities:
PURPOSE:Rituximab is a chimeric antibody that induces B-cell apoptosis and recruits immune effector cells to mediate cell lysis. Interleukin-12 (IL-12) facilitates cytolytic responses by T cells and natural killer cells. This phase II study was done to determine the efficacy and toxicity of IL-12 in combination with rituximab in patients with B-cell non-Hodgkin's lymphoma (NHL). EXPERIMENTAL DESIGN: Fifty-eight patients with histologically confirmed relapsed B-cell NHL were randomized to receive concurrent treatment with rituximab and IL-12 (arm A) or rituximab with subsequent treatment with IL-12 after documented nonresponse or progression after rituximab (arm B). Treatment consisted of 375 mg/m2 rituximab on days 1, 8, 15, and 22 and 300 ng/kg IL-12 given s.c. twice weekly starting on day 2 for arm A or upon progression for arm B. RESULTS: The overall response rate was 37% (11 of 30) in arm A and 52% (13 of 25) in arm B. All of the responses seen in arm B occurred while patients received rituximab, and no responses occurred during treatment with subsequent IL-12. The median duration of response was 16 months for arm A and 12 months for arm B. Biopsy specimens were serially obtained in a subset of patients and showed that changes in gene expression were different when cells from the peripheral blood were compared with cells from lymph node biopsies. CONCLUSIONS: The concomitant use of IL-12 and rituximab had modest disease activity in patients with B-cell NHL, but the sequential administration of IL-12 after rituximab did not result in additional clinical responses.
Authors: Maximillian Rosario; Bai Liu; Lin Kong; Lynne I Collins; Stephanie E Schneider; Xiaoyue Chen; Kaiping Han; Emily K Jeng; Peter R Rhode; Jeffrey W Leong; Timothy Schappe; Brea A Jewell; Catherine R Keppel; Keval Shah; Brian Hess; Rizwan Romee; David R Piwnica-Worms; Amanda F Cashen; Nancy L Bartlett; Hing C Wong; Todd A Fehniger Journal: Clin Cancer Res Date: 2015-09-30 Impact factor: 12.531
Authors: Xuefang Cao; Karen Leonard; Lynne I Collins; Sheng F Cai; Joshua C Mayer; Jacqueline E Payton; Michael J Walter; David Piwnica-Worms; Robert D Schreiber; Timothy J Ley Journal: Cancer Res Date: 2009-10-20 Impact factor: 12.701
Authors: Zhi-Zhang Yang; Deanna M Grote; Steven C Ziesmer; Toshiro Niki; Mitsuomi Hirashima; Anne J Novak; Thomas E Witzig; Stephen M Ansell Journal: J Clin Invest Date: 2012-03-19 Impact factor: 14.808
Authors: Courtney A Cohen; Amanda A Shea; C Lynn Heffron; Eva M Schmelz; Paul C Roberts Journal: J Interferon Cytokine Res Date: 2015-10-02 Impact factor: 2.607
Authors: Kavin Fatehchand; Li Ren; Saranya Elavazhagan; Huiqing Fang; Xiaokui Mo; John P Vasilakos; Gregory N Dietsch; Robert M Hershberg; Susheela Tridandapani; Jonathan P Butchar Journal: J Biol Chem Date: 2015-12-22 Impact factor: 5.157